AbbVie Inc.'s Stock Analysis

AbbVie Announces $7.95 Billion Senior Notes Offering

AbbVie Inc. has entered into an underwriting agreement to issue and sell various senior notes totaling approximately $7.95 billion. This includes $750 million in senior floating rate notes due 2028, and several other series of senior notes with maturities ranging from 2028 to 2066, with interest rates from 3.775% to 5.650%. The offering has been registered under the Securities Act and is expected to close on March 4, 2026, subject to customary conditions.

The net proceeds from this offering will primarily be used to repay amounts outstanding under AbbVie's $4.0 billion 364-Day delayed draw term loan facility, which is maturing in May 2026, as well as for general corporate purposes, including potential debt repayment or repurchase. The underwriting agreement includes standard representations and covenants by AbbVie, along with indemnification provisions for the underwriters. Additional details regarding the terms of the notes can be found in the accompanying prospectus supplements.

Feb 26, 2026 17:14:40

AbbVie Announces $7.95 Billion Senior Notes Offering

AbbVie Inc. has entered into an underwriting agreement to issue and sell $7.95 billion in senior notes, including various series of notes due between 2028 and 2066. The notes consist of senior floating rate notes and fixed-rate senior notes with varying interest rates, and the offering has been registered under the Securities Act of 1933. The public pricing for the notes ranges from 99.714% to 100.000% of the principal amount, depending on the specific series.

The net proceeds from this offering are intended to be used to repay outstanding amounts under a $4.0 billion term loan facility that matures in May 2026, as well as for general corporate purposes, which may include debt repayment or repurchase. The closing of the sale is expected to occur on March 4, 2026, subject to customary closing conditions. Additional details regarding the offering and terms of the notes are available in the preliminary and final prospectus supplements filed with the SEC.

Feb 26, 2026 17:14:40

AbbVie Reports Q4 and Full-Year 2025 Financial Results

AbbVie reported full-year 2025 net revenues of $61.160 billion, marking an 8.6% increase compared to the previous year. The company experienced growth in its immunology and neuroscience portfolios, with global net revenues of $30.406 billion and $10.767 billion, respectively. However, revenues from the aesthetics portfolio decreased by 6.1%. For the fourth quarter, AbbVie achieved net revenues of $16.618 billion, a 10.0% increase, with diluted EPS of $1.02 on a GAAP basis and adjusted diluted EPS of $2.71, which included an unfavorable impact from acquired IPR&D and milestones expense.

For 2026, AbbVie provided adjusted diluted EPS guidance of $14.37 to $14.57, excluding impacts from acquired IPR&D and milestones. The company also announced several recent developments, including a voluntary agreement with the Trump administration to enhance access to medications, submissions for new drug indications, and the acquisition of a manufacturing facility to support future product needs. These strategic moves aim to bolster AbbVie's growth and innovation in the pharmaceutical market.

Feb 04, 2026 07:54:33

AbbVie Reports Q4 2025 Earnings Guidance and Expenses

AbbVie anticipates that its fourth quarter 2025 GAAP and adjusted non-GAAP earnings will include an acquired IPR&D and milestones expense of $1.3 billion before tax, which is expected to negatively affect diluted earnings per share by $0.71. The full-year adjusted diluted earnings per share guidance for 2025 is projected to range from $9.90 to $9.94, while the fourth quarter adjusted diluted earnings per share guidance is estimated between $2.61 and $2.65, factoring in this expense.

The company noted that the results for the quarter ending December 31, 2025, are not finalized and may differ from the preliminary estimates provided. AbbVie does not predict future acquired IPR&D and milestones expenses due to uncertainties surrounding the timing and occurrence of related transactions. Additional information regarding risks and uncertainties that could influence AbbVie's operations is detailed in their filings with the Securities and Exchange Commission.

Jan 07, 2026 16:08:59

AbbVie Reports Third-Quarter 2025 Financial Results and Dividend Increase

AbbVie Inc. reported third-quarter 2025 financial results, with diluted earnings per share (EPS) of $0.10 on a GAAP basis, representing an 88.6% decrease, and adjusted diluted EPS of $1.86, a decrease of 38.0%. Net revenues for the quarter reached $15.776 billion, up 9.1% from the previous year, driven by strong performance in the immunology and neuroscience portfolios, which saw increases of 11.9% and 20.2%, respectively. However, revenues from the oncology and aesthetics portfolios experienced slight declines. The company has raised its adjusted diluted EPS guidance for the full year to a range of $10.61 to $10.65, accounting for an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expenses incurred year-to-date.

Additionally, AbbVie announced a 5.5% increase in its quarterly cash dividend, raising it from $1.64 to $1.73 per share, effective February 2026. This reflects AbbVie's commitment to returning cash to shareholders, as the company has increased its dividend by over 330% since its inception in 2013. The company is also advancing its pipeline with several new drug applications and clinical trial results that may further enhance its market position.

Oct 31, 2025 07:51:43

AbbVie Reports Significant Expenses Impacting Earnings Guidance

AbbVie anticipates a $2.7 billion expense related to acquired IPR&D and milestones for the third quarter of 2025, which is expected to reduce both GAAP and adjusted non-GAAP diluted earnings per share by $1.50. The company has provided a full-year adjusted diluted earnings per share guidance range of $10.38 to $10.58, which now includes this expense.

The adjusted diluted earnings per share guidance for the third quarter of 2025 is projected to be between $1.74 and $1.78, reflecting the impact of the acquired IPR&D and milestones expense. AbbVie has clarified that while these expenses may arise from collaborations and licensing agreements, they cannot be reliably forecasted beyond the current quarter.

Oct 03, 2025 16:09:03

AbbVie Settles Litigation on Upadacitinib Generic Manufacturing

AbbVie has reached a settlement with all generic manufacturers that filed applications for generic versions of its drug upadacitinib, marketed as RINVOQ. As a result of this settlement and the accompanying license agreements, AbbVie expects that no generic versions of upadacitinib will enter the U.S. market before April 2037, assuming pediatric exclusivity is granted.

This resolution is significant for AbbVie as it protects the market exclusivity of RINVOQ, potentially impacting the company's revenue from this product. The settlement also mitigates risks associated with litigation and challenges to its intellectual property, which could influence investor confidence and stock performance.

Sep 11, 2025 07:30:54

AbbVie Reports Second-Quarter 2025 Financial Results and Guidance

AbbVie announced its financial results for the second quarter of 2025, reporting a diluted earnings per share (EPS) of $0.52 on a GAAP basis, a decrease of 32.5%, while adjusted diluted EPS increased by 12.1% to $2.97. The company achieved net revenues of $15.423 billion, marking a 6.6% increase. Key contributors to revenue included the immunology portfolio, which generated $7.631 billion, and the neuroscience portfolio, which brought in $2.683 billion. However, revenues from the aesthetics portfolio decreased by 8.1% to $1.279 billion, driven by declines in Botox Cosmetic and Juvederm sales. AbbVie also raised its adjusted diluted EPS guidance for the full year to a range of $11.88 to $12.08, which accounts for an unfavorable impact of $0.55 per share from acquired IPR&D and milestones expenses incurred year-to-date through Q2 2025.

Recent developments included FDA approvals for Rinvoq and Emrelis, as well as positive results from clinical trials for several products, including Qulipta and Rinvoq in new indications. AbbVie also announced its acquisition of Capstan Therapeutics, which will enhance its pipeline with a potential first-in-class therapy for autoimmune diseases. The company continues to advance its oncology portfolio, with significant progress reported at the ASCO Annual Meeting. Despite a recent setback with the VERONA trial for Venclexta, AbbVie remains focused on innovation and expanding its therapeutic offerings across various medical fields.

Jul 31, 2025 07:48:24

AbbVie Reports Second Quarter 2025 Earnings Guidance Update

AbbVie anticipates a pre-tax expense of $823 million related to acquired IPR&D and milestones for the second quarter of 2025, which is expected to reduce both GAAP and adjusted non-GAAP diluted earnings per share by $0.42. The company has not finalized its results for the quarter ending June 30, 2025, and these preliminary estimates may change as financial statement closing procedures are completed.

For the full year 2025, AbbVie has updated its adjusted diluted earnings per share guidance to a range of $11.67 to $11.87, incorporating the anticipated second quarter expenses. The adjusted diluted earnings per share guidance for the second quarter is projected to be between $2.84 and $2.88, excluding any additional expenses from acquired IPR&D and milestones that may occur later in the year.

Jul 03, 2025 13:07:55

AbbVie Adjusts EPS Guidance Due to Acquired Expenses

AbbVie Inc. has updated its earnings per share (EPS) guidance for the second quarter and full year of 2025, reflecting the impact of acquired in-process research and development (IPR&D) and milestones expense. For Q2 2025, the adjusted diluted EPS is now projected to be between $2.84 and $2.88, after accounting for an expense of $823 million. This is a decrease from the previously announced guidance that did not include these expenses.

For the full year 2025, the adjusted diluted EPS guidance is now set between $11.67 and $11.87, with the same $823 million expense factored in. The guidance excludes any further IPR&D and milestones expenses that may arise after Q2 2025, as these costs cannot be reliably predicted at this time.

Jul 03, 2025 13:07:55